The paper by MB Vincent et 31. in this issue represents a further piece of investigation on the mechanism of action of sumatriptan. It focuses on the efficacy of the drug in aborting cluster headache ( CHj attacks, a clinical condition for which sumatriptan is highly effective and now represents the treatment of choice. The authors have chosen porcine ophthalmic artery ( POAj for evaluating the...

OBJECTIVE To evaluate the impact on costs and outcomes of early migraine treatment with sumatriptan while pain is mild versus sumatriptan treatment of moderate to severe pain. BACKGROUND Migraines result in substantial pain, impairment, and costs. Recent clinical studies have shown that early treatment with sumatriptan when migraine pain is mild is more effective than sumatriptan treatment wh...

background: sodium valproate (sv) has been approved for migraine prophylaxis and its intravenous form is used to treat acute migraine attacks. we compared the efficacy and safety of intravenous sv and subcutaneous sumatriptan in managing acute migraine attacks. methods: this double-blind randomized clinical trial divided 90 patients into two groups: one group received 400 mg of intravenous sv a...

The relatively low response rate, particularly in high peak users, raises concern about the representativeness of this study. When the higher total consumption of sumatriptan among non-respondents in this group is taken into consideration, this bias could lead to underestimation of sumatriptan overuse. Appropriate heavy use of sumatriptan for cluster headache was rare. We conclude that heavy co...

Eletriptan (Relpax, Pfizer) is one of a group of anti-migraine medications commonly referred to as 'triptans'. It is a potent serotonin agonist at the 5-HT(1B/1D) receptor and is indicated for the acute treatment of migraine headaches. Eletriptan is administered orally. It is rapidly absorbed and has a bioavailability of 50% compared to 14% for sumatriptan. The relatively high lipophilicity of ...

OBJECTIVE To evaluate the adverse events possibly caused by sumatriptan injection and explore the relationship between chest symptoms along with sumatriptan injection and coronary ischemia among Japanese patients with migraine. METHODS A cumulative total of 112 subcutaneous injections in 62 patients were evaluated. ECG was continuously monitored before and until 5 minutes after injection on 9...

OBJECTIVE To use a composite efficacy/tolerability end point to compare the cost-effectiveness, from the perspective of a U.S. health care payer, of almotriptan and sumatriptan in the treatment of an acute migraine attack. METHODS The composite end point. Sustained pain free and No Adverse Events. (SNAE) was created from the sustained pain free and adverse event rates obtained in a meta-analy...

Forty to 78% of the patients using sumatriptan for the acute treatment of migraine may present recurrence at least occasionally. The concomitant use of a NSAID (nonsteroidal anti-inflammatory drug) has been recommended to decrease the recurrence rate. Sixty seven patients that treated successfully 8 migraine attacks with 100 mg of sumatritpan PO and presented recurrence in at least 5 attacks we...

BACKGROUND Early treatment of migraine with sumatriptan 50 mg and 100 mg, while pain is mild, has been reported to enhance pain-free response 2 hours and 4 hours postdose and sustained pain-free response 2 to 24 hours postdose compared with treatment when pain has become moderate to severe. Early treatment with sumatriptan 50 mg and 100 mg also resulted in less redosing, which translated to a r...